Detailed safety analysis shows sacituzumab tirumotecan manageable in metastatic triple-negative breast cancer
A post-hoc safety analysis of the phase 3 OptiTROP-Breast01 trial found that sacituzumab tirumotecan's key adverse events arose mainly in ...
